Abstract
AbstractRheumatoid arthritis (RA) affects the joints and extra‐articular organs and poses a significant health care problem in the modern era. Although current standard treatment modalities successfully control RA flares, no curative treatment modality for RA has been developed. Nanomedicines have addressed the drug side effects and limited efficacy of RA treatment. However, synthetic nanoparticles (NPs) can be toxic and induce immune responses in vivo, posing a risk of further RA progression. Biomimetic nanodrug delivery systems have the potential to improve the biocompatibility of synthetic NPs and the stability and targeting of pharmaceuticals in vivo. For many immune‐related diseases with a complex pathogenesis and that involve a large number of different cell types, biomimetic nanodelivery systems can reduce the immunogenicity of NPs. Furthermore, some bioinspired strategies can mimic certain components of the pathological process, allowing for a more precise drug delivery and effective disease control via the carriers. This article highlights recent research on biomimetic nanodelivery systems for the treatment of RA and categorizes the design methodologies for various targets and carriers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
